PDF(1210 KB)
Analysis of KRAS Gene Mutation in Non-small Cell Lung Cancer
YIP Yuk Ching, CHAN Kin Iong, WEN Jian Ming, SIN Lai Fong, CHU Wai Kuou
Medical Journal of Kiang Wu ›› 2018, Vol. 18 ›› Issue (1) : 5-7.
PDF(1210 KB)
PDF(1210 KB)
Analysis of KRAS Gene Mutation in Non-small Cell Lung Cancer
Carcinoma / Non-small cell lung cancer / KRAS mutation {{custom_keyword}} /
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin, 2016; 66(1):7-30.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China. CA Cancer J Clin, 2016; 66(2):115-132.
[3] Sher T, Dy GK, Adkei AA. Small cell lung cancer. Mayo Clin Proc, 2008; 83(3):355-367.
[4] Burgess TL, Sun J, Meyer S, et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther, 2010; 9(2):400-409.
[5] 在2014年最常見的新登記癌症及死亡個案.《2014澳門癌症登記年報》, 2016; 6:6-10. issn:18140009.
[6] Harris T. Does large scale DNA sequencing of patient and tumor DNA yet provide clinically actionable information? Discov Med, 2010; 10:144-150.
[7] Kris MG, Johnson BE. Berry LD, et al. Using multiplexed assays of oncogenes drivers in lung cancers to select targeted drugs. JAMA, 2014; 311(19):1998-2006.
[8] Forbes S, Clements J, Dawson E, et al. CPSMIC 2005. Br J Cancer, 2006, 94(2):318-322.
[9] Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004; 101(36):13306-13311.
[10] Pao W, Wang TY, Riely GJ, et a1. KRAS mutation and primary resis- tance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2005; 2(1):e17.
[11] Zhu CQ, Da Cunha Santos G, Ding K, et a1. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol, 2008; 26(26):4268-4275.
[12] Massarelli E, Varelia Garcia M, Tang X. et a1. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res, 2007; 13(10):2890-2896.
[13] Sun JM, Hwang DW, Ahmad JS, et al. Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. PLoS One, 2013. http://www.ncbi.nlm. nih.gov/pic/articles /PMC3665805/.
[14] 張潔霞, 李時悅, 占揚清, 等. 中國非小細胞肺癌患者K-Ras和EGFR 基因突變與臨床病理特徵的關係. 臨床腫瘤學雜志, 2014; 19(9):799-803.
[15] 羅煒, 王慧, 徐韞健, 等. 非小細胞肺癌患者KRAS基因突變情況分析. 廣東醫學, 2014; 35(13):2025-2028.
[16] Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res, 2008; 14(18):5731-5734.
[17] 張卉, 楊新杰, 秦娜, 等. 肺腺癌EGFR與KRAS基因突變狀態分析. 中國肺癌雜志, 2015; 18(11):686-690.
[18] 衣素琴, 莊嚴, 朱衛東, 等. 非小細胞肺癌中KRAS 基因突變分析. 中華臨床醫師雜志(電子版), 2013; 7(20):9111-9115.
[19] Kim HR, Ahn JR, Lee JG, et al. The impact of Cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. Yonsei Med J, 2013; 54:865-874.
[20] 中國非小細胞肺癌患者表皮生長因子受體基因突變檢測專家組. 中國非小細胞肺癌患者表皮生長因子受體基因突變檢測專家共識, 中華病理學雜志, 2011; 40(10):700-702.
PDF(1210 KB)
/
| 〈 |
|
〉 |
